The Evaluation of Novel Targets for CAR T therapy in Myeloma
Research type
Research Study
Full title
The Evaluation of Novel Targets for CAR T therapy in glioblastoma and myeloma
IRAS ID
312499
Contact name
Peter Abel
Contact email
Duration of Study in the UK
1 years, 3 months, days
Research summary
Summary of Research
Chimeric antigen receptor T cell (CAR T) therapy utilises a target molecule for cell-mediated destruction of a tumour cell. The therapy has shown impressive clinical responses in some blood cancers but is less successful in myeloma, due to the changing nature of the disease in which the current viable target evades the immune cells through mutation. This research is looking for an off-tumour cell target that may overcome the mutation problem as described by looking for a target molecule involved in the spread of the tumour through the blood vessels. Newly diagnosed patients of ≥ 18 with symptomatic or asymptomatic myeloma and non- myeloma conditions undergoing marrow biopsy procedures are eligible.
The project will utilise slices (7-14) trephine of solid tumour biopsy prepared from a standard of care paraffin block from the patient’s bone marrow. The investigators will analyse the prevalence and distribution of the target molecules in the biopsy. The project also requires patients’ demographics (age, sex, and ethnicity) to evaluate how these might correlate to the treatment. As the condition of the patients is unknown at the point of consent, the data would be looked at retrospectively following full diagnosis. Additionally, the project will analyse the target’s blood concentration to explore its potential as a treatment response biomarker. The study is multicentre involving East Lancashire Hospital Trust (ELHT), Macclesfield District General Hospital and Wrightington, Wigan and Leigh (WWL) NHS Foundation Trust as recruitment sites. The recruited timeframe is five months, and the study will last for approximately one year and three months. The solid biopsy will be processed at Leeds and The Christie trusts, depending on where the participants are recruited while serum goes directly to UCLan from the recruitment sites. The research samples will be analysed at the Biomedical Research Facility, Darwin Building, UCLan PR1 2HE.Summary of Results
No results obtained due to insufficient sample size.
REC name
West of Scotland REC 5
REC reference
22/WS/0151
Date of REC Opinion
10 Nov 2022
REC opinion
Further Information Favourable Opinion